Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertensi… Read more
Glenmark Pharmaceuticals Limited (GLENMARK) - Net Assets
Latest net assets as of September 2025: ₹95.82 Billion INR
Based on the latest financial reports, Glenmark Pharmaceuticals Limited (GLENMARK) has net assets worth ₹95.82 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹190.02 Billion) and total liabilities (₹94.20 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹95.82 Billion |
| % of Total Assets | 50.42% |
| Annual Growth Rate | 18.87% |
| 5-Year Change | 25.27% |
| 10-Year Change | 107.24% |
| Growth Volatility | 30.42 |
Glenmark Pharmaceuticals Limited - Net Assets Trend (2004–2025)
This chart illustrates how Glenmark Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Glenmark Pharmaceuticals Limited (2004–2025)
The table below shows the annual net assets of Glenmark Pharmaceuticals Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹88.49 Billion | +12.76% |
| 2024-03-31 | ₹78.48 Billion | -20.24% |
| 2023-03-31 | ₹98.39 Billion | +4.25% |
| 2022-03-31 | ₹94.38 Billion | +33.60% |
| 2021-03-31 | ₹70.64 Billion | +16.38% |
| 2020-03-31 | ₹60.70 Billion | +8.30% |
| 2019-03-31 | ₹56.05 Billion | +0.29% |
| 2018-03-31 | ₹55.89 Billion | +13.15% |
| 2017-03-31 | ₹49.39 Billion | +15.67% |
| 2016-03-31 | ₹42.70 Billion | +42.32% |
| 2015-03-31 | ₹30.00 Billion | +0.12% |
| 2014-03-31 | ₹29.97 Billion | +7.50% |
| 2013-03-31 | ₹27.87 Billion | +14.87% |
| 2012-03-31 | ₹24.27 Billion | +17.57% |
| 2011-03-31 | ₹20.64 Billion | -12.85% |
| 2010-03-31 | ₹23.68 Billion | +47.89% |
| 2009-03-31 | ₹16.01 Billion | +5.39% |
| 2008-03-31 | ₹15.19 Billion | +121.36% |
| 2007-03-31 | ₹6.86 Billion | +74.60% |
| 2006-03-31 | ₹3.93 Billion | +19.50% |
| 2005-03-31 | ₹3.29 Billion | +40.10% |
| 2004-03-31 | ₹2.35 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Glenmark Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8798539000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹87.99 Billion | 99.42% |
| Common Stock | ₹282.19 Million | 0.32% |
| Other Comprehensive Income | ₹-16.64 Billion | -18.80% |
| Other Components | ₹16.87 Billion | 19.06% |
| Total Equity | ₹88.49 Billion | 100.00% |
Glenmark Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Glenmark Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NEXON Co. Ltd
PINK:NEXOF
|
$3.55 Billion |
|
Celcuity LLC
NASDAQ:CELC
|
$3.55 Billion |
|
Munters Group AB (publ)
OTCGREY:MMNNF
|
$3.55 Billion |
|
SUNRISE N
SW:SUNN
|
$3.55 Billion |
|
Sembcorp Industries Ltd
PINK:SCRPF
|
$3.54 Billion |
|
BKW AG
PINK:BKWAF
|
$3.54 Billion |
|
Cabot Corporation
NYSE:CBT
|
$3.54 Billion |
|
Hitachi Energy India Limited
NSE:POWERINDIA
|
$3.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Glenmark Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 78,479,270,000 to 88,494,410,000, a change of 10,015,140,000 (12.8%).
- Net income of 10,470,970,000 contributed positively to equity growth.
- Dividend payments of 704,420,000 reduced retained earnings.
- Other comprehensive income increased equity by 734,230,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹10.47 Billion | +11.83% |
| Dividends Paid | ₹704.42 Million | -0.8% |
| Other Comprehensive Income | ₹734.23 Million | +0.83% |
| Other Changes | ₹-485.64 Million | -0.55% |
| Total Change | ₹- | 12.76% |
Book Value vs Market Value Analysis
This analysis compares Glenmark Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 212.85x to 6.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹10.20 | ₹2170.70 | x |
| 2005-03-31 | ₹12.61 | ₹2170.70 | x |
| 2006-03-31 | ₹14.58 | ₹2170.70 | x |
| 2007-03-31 | ₹25.65 | ₹2170.70 | x |
| 2008-03-31 | ₹59.94 | ₹2170.70 | x |
| 2009-03-31 | ₹62.61 | ₹2170.70 | x |
| 2010-03-31 | ₹90.13 | ₹2170.70 | x |
| 2011-03-31 | ₹75.33 | ₹2170.70 | x |
| 2012-03-31 | ₹88.74 | ₹2170.70 | x |
| 2013-03-31 | ₹102.00 | ₹2170.70 | x |
| 2014-03-31 | ₹110.02 | ₹2170.70 | x |
| 2015-03-31 | ₹110.57 | ₹2170.70 | x |
| 2016-03-31 | ₹152.08 | ₹2170.70 | x |
| 2017-03-31 | ₹175.00 | ₹2170.70 | x |
| 2018-03-31 | ₹198.05 | ₹2170.70 | x |
| 2019-03-31 | ₹198.64 | ₹2170.70 | x |
| 2020-03-31 | ₹215.14 | ₹2170.70 | x |
| 2021-03-31 | ₹250.37 | ₹2170.70 | x |
| 2022-03-31 | ₹322.03 | ₹2170.70 | x |
| 2023-03-31 | ₹335.75 | ₹2170.70 | x |
| 2024-03-31 | ₹278.12 | ₹2170.70 | x |
| 2025-03-31 | ₹313.58 | ₹2170.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Glenmark Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.83%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.84%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 1.81x
- Recent ROE (11.83%) is below the historical average (17.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 17.65% | 10.87% | 0.84x | 1.94x | ₹179.24 Million |
| 2005 | 32.56% | 17.50% | 0.67x | 2.79x | ₹742.18 Million |
| 2006 | 22.38% | 11.61% | 0.56x | 3.44x | ₹486.65 Million |
| 2007 | 45.17% | 24.77% | 0.64x | 2.83x | ₹2.41 Billion |
| 2008 | 41.65% | 31.46% | 0.68x | 1.94x | ₹4.80 Billion |
| 2009 | 12.11% | 9.14% | 0.50x | 2.66x | ₹336.57 Million |
| 2010 | 14.06% | 13.24% | 0.51x | 2.07x | ₹955.08 Million |
| 2011 | 22.47% | 15.52% | 0.58x | 2.50x | ₹2.54 Billion |
| 2012 | 19.17% | 11.45% | 0.68x | 2.45x | ₹2.20 Billion |
| 2013 | 22.44% | 12.46% | 0.69x | 2.60x | ₹3.44 Billion |
| 2014 | 18.18% | 9.12% | 0.69x | 2.89x | ₹2.44 Billion |
| 2015 | 15.84% | 7.25% | 0.68x | 3.23x | ₹1.75 Billion |
| 2016 | 16.44% | 9.27% | 0.70x | 2.54x | ₹2.75 Billion |
| 2017 | 18.54% | 10.09% | 0.74x | 2.47x | ₹4.22 Billion |
| 2018 | 14.38% | 8.86% | 0.70x | 2.33x | ₹2.45 Billion |
| 2019 | 16.50% | 9.38% | 0.74x | 2.37x | ₹3.64 Billion |
| 2020 | 12.78% | 7.28% | 0.73x | 2.42x | ₹1.69 Billion |
| 2021 | 13.73% | 8.86% | 0.70x | 2.21x | ₹2.64 Billion |
| 2022 | 10.36% | 7.65% | 0.72x | 1.88x | ₹330.46 Million |
| 2023 | 3.14% | 2.55% | 0.60x | 2.04x | ₹-6.50 Billion |
| 2024 | -19.13% | -11.88% | 0.88x | 1.83x | ₹-22.86 Billion |
| 2025 | 11.83% | 7.84% | 0.83x | 1.81x | ₹1.62 Billion |
Industry Comparison
This section compares Glenmark Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,182,683,300
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Glenmark Pharmaceuticals Limited (GLENMARK) | ₹95.82 Billion | 17.65% | 0.98x | $3.55 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $11.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $351.56 Million |
| Abbott India Limited (ABBOTINDIA) | $11.96 Billion | 21.35% | 0.35x | $1.60 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.51 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.79 Million |
| Albert David Limited (ALBERTDAVD) | $1.86 Billion | 5.29% | 0.56x | $16.25 Million |
| Alivus Life Sciences Limited (ALIVUS) | $21.38 Billion | 21.84% | 0.26x | $329.34 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $1.71 Billion | 11.38% | 0.30x | $5.51 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $81.74 Million |